Radius Reveals Abaloparatide Delay, After Playing Up Launch Readiness
FDA's review of filing for osteoporosis abaloparatide delayed by three months to June 30, bringing it closer to the action date for Amgen's competing anabolic agent romosuzumab, which has an action date of July 19.
You may also be interested in...
Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market
At $19,500 per year, Radius Health's Tymlos (abaloparatide) is priced to compete with Lilly's similar, but well-established drug Forteo. The company hopes to increase the size of the osteoporosis market to achieve its blockbuster sales goal, but at least one analyst has her doubts.
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.